These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 12227060)

  • 21. Resistance to trastuzumab: a necessary evil or a temporary challenge?
    Cardoso F; Piccart MJ; Durbecq V; Di Leo A
    Clin Breast Cancer; 2002 Oct; 3(4):247-57; discussion 258-9. PubMed ID: 12425752
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HER2 testing in breast cancer: NCCN Task Force report and recommendations.
    Carlson RW; Moench SJ; Hammond ME; Perez EA; Burstein HJ; Allred DC; Vogel CL; Goldstein LJ; Somlo G; Gradishar WJ; Hudis CA; Jahanzeb M; Stark A; Wolff AC; Press MF; Winer EP; Paik S; Ljung BM;
    J Natl Compr Canc Netw; 2006 Jul; 4 Suppl 3():S1-22; quiz S23-4. PubMed ID: 16813731
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Growth and molecular interactions between tamoxifen and trastuzumab.
    Vázquez-Martín A; Colomer R; Ropero S; Abel Menéndez J; Argiris A; Wang CX; Koay DC; Digiovanna MP
    Clin Cancer Res; 2005 May; 11(9):3597; author reply 3597-9. PubMed ID: 15867265
    [No Abstract]   [Full Text] [Related]  

  • 24. Targeted therapy for cancer: the HER-2/neu and Herceptin story.
    Ross JS; Gray GS
    Clin Leadersh Manag Rev; 2003; 17(6):333-40. PubMed ID: 14692077
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
    Pegram M; Hsu S; Lewis G; Pietras R; Beryt M; Sliwkowski M; Coombs D; Baly D; Kabbinavar F; Slamon D
    Oncogene; 1999 Apr; 18(13):2241-51. PubMed ID: 10327070
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How do you tell whether a breast cancer is HER2 positive? Ongoing studies keep debate in high gear.
    Schmidt C
    J Natl Cancer Inst; 2011 Jan; 103(2):87-9. PubMed ID: 21191114
    [No Abstract]   [Full Text] [Related]  

  • 27. Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER2).
    van de Vijver MJ
    Eur J Cancer; 2001 Jan; 37 Suppl 1():S11-7. PubMed ID: 11167086
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inconsistency of HER2 test raises questions.
    Tuma RS
    J Natl Cancer Inst; 2007 Jul; 99(14):1064-5. PubMed ID: 17623788
    [No Abstract]   [Full Text] [Related]  

  • 29. Her2 and trastuzumab in breast cancer.
    Horton J
    Cancer Control; 2001; 8(1):103-10. PubMed ID: 11176040
    [No Abstract]   [Full Text] [Related]  

  • 30. ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines.
    Ginestier C; Adélaïde J; Gonçalvès A; Repellini L; Sircoulomb F; Letessier A; Finetti P; Geneix J; Charafe-Jauffret E; Bertucci F; Jacquemier J; Viens P; Birnbaum D
    Oncogene; 2007 Nov; 26(50):7163-9. PubMed ID: 17525746
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HER2/neu in the management of invasive breast cancer.
    Meric F; Hung MC; Hortobagyi GN; Hunt KK
    J Am Coll Surg; 2002 Apr; 194(4):488-501. PubMed ID: 11949754
    [No Abstract]   [Full Text] [Related]  

  • 32. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
    Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trial watch: ERBB2 dimerization inhibitor meets end point in breast cancer trial.
    Nat Rev Drug Discov; 2011 Aug; 10(9):648. PubMed ID: 21878970
    [No Abstract]   [Full Text] [Related]  

  • 34. [HER-2/neu oncogene in the selection of treatment for breast cancer and as a target of immunotherapy].
    Isola J; Järvinen T; Tanner M; Holli K
    Duodecim; 2000; 116(15):1538-46. PubMed ID: 12001473
    [No Abstract]   [Full Text] [Related]  

  • 35. Will single-time tumor profiling and a "guilt by association" approach allow us to outsmart HER2-positive breast cancer?
    Arteaga CL
    Clin Cancer Res; 2007 Feb; 13(4):1071-3. PubMed ID: 17317812
    [No Abstract]   [Full Text] [Related]  

  • 36. Role of erbB2 in breast cancer chemosensitivity.
    Yu D; Hung MC
    Bioessays; 2000 Jul; 22(7):673-80. PubMed ID: 10878580
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Meningeal carcinomatosis in HER2-overexpressing breast cancers.
    Bidard FC; Guilhaume MN; Gauthier H; Cottu PH; Diéras V; Pierga JY
    J Neurooncol; 2009 Jun; 93(2):287-8. PubMed ID: 19139826
    [No Abstract]   [Full Text] [Related]  

  • 38. Re: Effect of gamma-linolenic acid on the transcriptional activity of the Her-2/neu (erbB-2) oncogene.
    Das UN
    J Natl Cancer Inst; 2006 May; 98(10):718; author reply 718-20. PubMed ID: 16705127
    [No Abstract]   [Full Text] [Related]  

  • 39. HER2 and proliferation of wound-induced breast carcinoma.
    Mannello F; Papa S
    Lancet; 2003 Nov; 362(9394):1503-4. PubMed ID: 14602458
    [No Abstract]   [Full Text] [Related]  

  • 40. Cell line standards to reduce HER-2/neu assay variation and the potential of automated image analysis to provide more accurate cut points for predicting clinical response to trastuzumab.
    Jasani B; Miller K
    Am J Clin Pathol; 2005 Feb; 123(2):314; author reply 314-5. PubMed ID: 15842059
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.